Latest Conference Articles

Patients with scalp and body psoriasis who used nonsteroidal roflumilast foam .3% once daily experienced significant symptom improvement as early as 2 weeks.

Results presented at ACG 2023 demonstrated the viability of the HOMA-IR model for calculating insulin resistance to identify lean NAFLD.

New PUNCH CD3 analyses show patients who were treated with live fecal microbiota therapy improved their gut health at 8 weeks—which correlated with improved quality-of-life scores.

Feuerstadt reviews ACG 2023 data showing live microbiota therapy provides consistent protection against rCDI in one of the most vulnerable patient populations.

The UCLA hepatologist discusses the current treatment landscape, prospects for improved diagnostics, and the overlap syndrome live from ACG 2023.

A multi-target stool RNA test effectively screened individuals age 45 and older for colorectal cancer and advanced adenomas.

The investigator discusses the unique interplay between conditions like IBD and gestational risks—and how specialists need to improve communication.

No catch-all drug works to treat irritable bowel syndrome with constipation. But as the Mayo Clinic expert explains, enough unique options exist to tailor care better than ever.

Induction treatment with guselkumab resulted in a rapid onset of efficacy, beginning at week 1 and increasing over time to week 12, for patients with refractory moderately to severely active ulcerative colitis.

Etrasimod demonstrated rapid and significant symptomatic improvement, with differences compared to placebo evident as early as 2 days after initiation of treatment in patients with ulcerative colitis.

Study author Uma Mahadevan, MD, discusses her team's findings suggesting the concern of IBD flare risk in pregnant women receiving aspirin to prevent preeclampsia is unwarranted.

Completion of prescription app-based cognitive behavioral therapy using Mahana IBS significantly reduced symptom severity and perceived stress for patients with irritable bowel syndrome.

The study author discusses the clinical implications of his team's assessment into a risk factor score for alcohol relapse among post-transplant patients with ALD.

Results from the 104-week extension study were presented at ACG 2023, demonstrating mirikizumab’s favorable safety and efficacy profiles.

Investigator Brian E. Lacy, MD, PhD discusses new post hoc analysis that he hopes will provided clearer expectations for timing of benefit with tenapanor.

In his ‘Early Dermatology Practice Pearls’ presentation, Dr. Song described tips for dermatologists. In this interview segment, he continues this discussion.

Advanced therapies for inflammatory bowel disease, namely small molecules and biologic therapies, did not increase the risk of a major adverse cardiovascular event or venous thromboembolism.

Dr. Song spoke in this segment of his interview on several more insightful elements from his presentation titled ‘Early Dermatology Practice Pearls.’

Consumption of fruit and vegetables was found to be protective while consuming sweet snacks and candy along with supercenters and warehouse clubs as a primary food source were determined to be risk factors for early onset colorectal cancer mortality.

Investigator Jiten P. Kothadia, MD, discusses the advent of a predictive score for alcohol relapse risk in patients with alcohol liver disease who received a liver transplant in the last year.

The 15 mg dose of tirzepatide was the most efficacious GLP-1 agonist for obesity management in patients without diabetes in a systemic review of data from MEDLINE and Embase databases.

In this interview segment, Dr. Song provided several unique viewpoints presented in his conference talk ‘Early Dermatology Practice Pearls.’

Presented at ACG 2023, findings from a retrospective cohort analysis revealed patients with ALD diagnosed with and prescribed at least 1 medication for alcohol use disorder had a decreased risk of mortality.

Patients with plaque psoriasis, including in intertriginous areas and genitalia, experienced rapid improvement when treated with tapinarof cream 1%, offering an effective and well-tolerated nonsteroidal option for this condition.

Thomas F. Imperiale, MD, discusses the pivotal findings showing improvements to the prior iteration of Cologuard, as well as bettered sensitivity and specificty relative to fecal immunochemical tests.

Data presented at ACG 2023 shows a significantly increased risk of infection and hospitalization due to RSV in patients with IBD. An investigator discusses implications during an era of increased vaccine options.

Dr. Eichenfield used this interview segment to respond to the FDA’s recent decision not to approve dupilumab for chronic spontaneous urticaria.

New phase 1b data supports further investigation into Adiso Therapeutic's prospective treatment.

Post-hoc analysis clarifies efficacy of upadacitinib for patients with moderately to severely active Crohn's disease with a CDAI of 220 or more.

New data presented at ACG 2023 showed an approximate 60% success rate of recurrent C difficile prevention in adults with comorbid conditions including CKD and cardiac disease.